TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04754672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous aerobic and resistance exercise intervention
Description: Continuous aerobic and resistance exercises intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous aerobic and aerobic interval exercise intervention
Description: Continuous aerobic and aerobic interval exercise intervention
Study: NCT06430541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
Study: NCT06296914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POTSapp
Description: Participants will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months. T

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Participants will receive educational information about online support for POTS via email. Starting at month 4, participants will receive equipment will be asked to document symptoms daily in the mHealth app and will be asked to conduct an at home stand test biweekly through the mHealth app. These participants will be asked to take an online survey at baseline, at 4 months, and at 8 months.
Study: NCT04185337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo ultrasound-guided FNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo ultrasound-guided lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo ultrasound-guided PAI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT) acuity instrument
Description: Use multispectral optoacoustic tomography (MSOT) acuity instrument
Study: NCT05865379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BUFY01 eye drops in single-dose containers
Description: 1 to 2 drops in each eye, as often as needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVS20 eye drops in single-dose containers
Description: 1 to 2 drops in each eye, as often as needed
Study: NCT05504798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical therapy program
Description: Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical therapy program
Description: Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical therapy program
Description: Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted serial casting
Description: Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted serial casting
Description: Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
Study: NCT05018403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous AON-D21
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study: NCT04191447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flamboyant 200/12
Description: Flamboyant 200/12 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide / Formoterol 400/12
Description: Budesonide / Formoterol 400/12 capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamboyant 200/12 Placebo
Description: Flamboyant 200/12 Placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Budesonide / Formoterol 400/12 Placebo
Description: Budesonide / Formoterol 400/12 Placebo capsule
Study: NCT05263804

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
Description: No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with gadolinium injection - Ancillary Study
Description: Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
Study: NCT04540835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavity pretreatment (Teethmate Desensitizer, Kuraray)
Description: Calcium phosphate desensitizer applied after caries removal. After restored using an oblique incremental technique with a composite resin (Filtek Z250, 3M Espe, USA)
Study: NCT06638606

Intervention type: BEHAVIORAL
Intervention: Sleep improvement techniques
Description: Insomniac and hypersomniac individuals are given behavioral counselling to improve sleep.
Study: NCT05265273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.
Study: NCT06637891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 2 weeks, 3 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
Study: NCT06492954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
Study: NCT06186479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aconite pain oil
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Study: NCT06492954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
Study: NCT05567185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.
Study: NCT06386874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Sham
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Sham
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Active
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Active
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study: NCT06431438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study: NCT04837508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study: NCT06431438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

Intervention type: DRUG
Group type: OTHER
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study: NCT06281418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: 2mL intraperitoneal adminstration of granisetron (1 mg/mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml IP normal saline (0.9% NaCl)
Study: NCT05179876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan/Tadalafil FDC
Description: Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
Study: NCT06470438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88998377
Description: JNJ-88998377 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88998377
Description: JNJ-88998377 will be administered.
Study: NCT06324019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: putting on an examination gown
Description: During the gynecological examination, the patient in the experimental group will be made to wear an examination gown, while the patient in the control group will use the routine practice of the hospital. In this way, with the gynecological examination clothing to be developed, the body privacy of the patients will be protected during the examination. In addition, women will feel less anxiety during gynecological examination and important steps will be taken in maintaining women\&#39;s health by ensuring regular gynecological examination.
Study: NCT05769400

Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
Study: NCT04575363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample
Study: NCT04941157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal Fluid Drain Placement
Description: Prophylactic CSF Spinal Drain to be placed prior to surgery in patients randomized to the experimental arm of the study
Study: NCT06254898

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child life standard of care
Description: Standard preparation and support provided to the participant by a Certified Child Life Specialist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child life standard of care + incentives provided with conditional agreement.
Description: Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child life standard of care + incentive provided unconditionally.
Description: Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
Study: NCT05388058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05687916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-861 placebo matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861 2 mg
Description: TAK-861 2 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861 2 mg and 5 mg
Description: TAK-861 2 mg and 5 mg tablets.
Study: NCT06200259

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spot Delete planning for proton therapy
Description: The method of adjusting the placement of proton spots or targets that are placed by the treatment planning system during pencil beam scanning for proton therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Traditional proton treatment planning system
Description: In the control arm, the proton spots placed by the treatment planning system are not modified.
Study: NCT05443737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component oncofertility care intervention
Description: The multi-component oncofertility care intervention includes: (1) an adaptive and smart default electronic health record-based oncofertility needs screen and referral pathway, (2) telehealth oncofertility counseling as indicated, and (3) telehealth oncofertility financial navigation as indicated.
Study: NCT06581328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC injection
Study: NCT05425992

Intervention type: OTHER
Intervention: Interview
Description: Patient/parent dyads expressing interest will be interviewed by a bilingual Spanish certified provider via televideo with as needed interpreter support. Interviews will be audio recorded for review and translation purposes and then will be destroyed. Interview format will be supportive and information seeking only with reassurance that purpose is for care improvement and that all answers will be evaluated without association to patient name. Interviews will then be translated and reviewed by the PI for themes regarding perceived clinic successes and perceived clinic barriers in communication or care.
Study: NCT06101251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driving Tips
Description: Each week participants will receive a safe driving tip for one of the four behaviors via text message.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driving Tips
Description: Each week participants will receive a safe driving tip for one of the four behaviors via text message.
Study: NCT06523231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella4V2
Description: Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella4V2
Description: Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.
Study: NCT05776056

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: Methylphenidate 10mg will be taken twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: Methylphenidate 10mg will be taken twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An inactive pill (placebo) will be taken twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An inactive pill (placebo) will be taken twice daily.
Study: NCT06523231

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MenACWY
Description: Control vaccine
Study: NCT05970276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Sleep (N3) Enhancement with TES
Description: As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When slow wave sleep is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes.
Study: NCT05709951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Exercises
Description: The patients were requested to perform these functional exercises for 4 days per week three times for 20 min (8 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability Exercises
Description: The patients were requested to perform 4 core strengthening exercises for 4 days per week three times for 20 min (8 weeks)
Study: NCT05168423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-EGFR-IL13Ra2 Cells
Description: autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
Study: NCT06219824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: premixed Bio-ceramic MTA
Description: pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional MTA
Description: pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
Study: NCT05168423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-EGFR-IL13Ra2 Cells
Description: autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-EGFR-IL13Ra2 Cells
Description: autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-EGFR-IL13Ra2 Cells
Description: autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
Study: NCT05092841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT3003
Description: Patients will be administered PXT3003 twice daily (bid) at 10mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PXT3003 placebo
Description: Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.